Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 9/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2BRAFTP53 | |
| SCHEMBL29079 | 0.83 | BRAF (0.46) | BRAFTP53 | |
| SCHEMBL29063 | 0.82 | HTT (0.44) | CTNNB1TCF7L2SMN1; SMN2TP53PTGER4 | |
| SCHEMBL30795981 | 0.82 | L3MBTL1 (0.49) | SMN1; SMN2TP53PTGER4HTT | |
| SCHEMBL21060 | 0.82 | L3MBTL1 (0.49) | SMN1; SMN2TP53PTGER4HTT | |
| SCHEMBL22560 | 0.82 | SMN1; SMN2 (0.42) | CTNNB1TCF7L2SMN1; SMN2PTGER4HTT | |
| SCHEMBL30795823 | 0.82 | SMN1; SMN2 (0.42) | CTNNB1TCF7L2SMN1; SMN2PTGER4HTT | |
| SCHEMBL30794603 | 0.81 | HTT (0.43) | CTNNB1TCF7L2SMN1; SMN2PTGER4HTT | |
| SCHEMBL22677 | 0.81 | HTT (0.43) | CTNNB1TCF7L2SMN1; SMN2PTGER4HTT | |
| SCHEMBL22574 | 0.81 | KCNQ3 (0.56) | SMN1; SMN2TP53PTGER4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | claimed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | claimed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | claimed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CTNNB1 2860/4885TCF7L2 2521/4885SMN1; SMN2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.